

Supplemental Online Content

Mair MJ, Berger JM, Berghoff AS, et al. Humoral immune response in hematological patients and health care workers who received SARS-CoV-2 vaccinations. *JAMA Oncol*. Published online September 30, 2021. doi:10.1001/jamaoncol.2021.5437


eFigure. Anti-S levels after the second dose according to applied treatment in patients with solid tumors

eTable 1. Confirmed SARS-CoV-2 infections and anti-NC detection rates in hematological patients

eTable 2. Health care workers' cohort

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure. Anti-S levels after the second dose according to applied treatment in patients with solid tumors (other including hormonal therapy, radiotherapy and bisphosphonates).



eTable 1. Confirmed SARS-CoV-2 infections and anti-NC detection rates in hemato-oncological patients. Cut-off for anti-NC antibody positivity was used as recommended by the manufacturer.

		Past SARS-CoV-2 infection (confirmed by rt-PCR)		
		+	-	
anti-NC antibodies	+	4 (3.6%)	3 (2.7%)	Vienna cohort (n = 111)
	-	1 (0.9%)	103 (92.8%)	
	+	31 (6.7%)	11 (2.4%)	Meran cohort (n = 462)
	-	7 (1.5%)	413 (89.4%)	

eTable 2. Health care workers' cohort.

	Health care workers cohort (n = 58)
Age (median, range)	42 (24 – 60)
Gender	
- Male	18 (31.0%)
- Female	40 (69.0%)
Profession	
- Physician/medical oncologist	19 (32.8%)
- Nurse	24 (41.4%)
- Administrative staff	6 (10.3%)
- Other (biomedical analysts, scientific assistants, dieticians)	9 (15.5%)
Primary working environment	
- Inpatient ward/day hospital unit	37/58 (63.8%)
- Outpatient department	13/58 (22.4%)
- No direct contact with patients (administrative and scientific staff)	8/58 (13.8%)
Pre-vaccination (baseline)	n = 58
Verified SARS-CoV-2 infection	2 (3.4%)
Positive anti-NC antibodies	3 (5.2%)
Longitudinal cohort	n = 49
Used vaccine	
- BioNTech/Pfizer (BNT162b2)	33 (67.3%)
- AstraZeneca (AZD1222)	10 (20.4%)
- No vaccination	6 (12.2%)
1st follow-up (3-5 weeks after launch of the institutional vaccination campaign, n = 48)	
Verified SARS-CoV-2 infection	3 (6.3%)
Positive anti-NC antibodies	4 (8.3%)
Vaccination status	
- unvaccinated	17 (35.4%)
- 1 dose	31 (64.6%)
- 2 doses	0 (0.0%)
2nd follow-up (8-12 weeks after launch of the institutional vaccination campaign, n = 48)	
Verified SARS-CoV-2 infection	4 (8.3%)
Positive anti-NC antibodies	5 (10.4%)
Vaccination status	
- unvaccinated	8 (16.7%)
- 1 dose	9 (18.8%)
- 2 doses	31 (64.6%)